Four cases of tendinopathy in patients on statin therapy

被引:52
作者
Chazerain, P
Hayem, G
Hamza, S
Best, C
Ziza, JM
机构
[1] Hop Croix St Simon, Dept Rheumatol & Internal Med, F-75960 Paris 20, France
[2] Hop Bichat Claude Bernard, Dept Rheumatol, F-75018 Paris, France
关键词
causality of adverse events; statin; tendinopathy;
D O I
10.1016/S1297-319X(01)00300-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During the last decade, statins have been widely prescribed as lipid-lowering drugs. Their overall safety profile is good. The main musculoskeletal side effects have consisted of muscle pain and weakness, peripheral neuropathy, and a few cases of drug-induced lupus. We report the first four cases of tendinopathy in patients receiving statin therapy. There were three men and one woman. The diagnoses were extensor tenosynovitis at the hands (case 1), tenosynovitis of the tibialis anterior tendon (case 2), and Achilles tendinopathy (cases 3 and 4). Two patients were on simvastatin and two on atorvastatin. The tendinopathy developed 1 to 2 months after treatment initiation. The outcome was consistently favorable within 1 to 2 months after discontinuation of the drug. Similar cases have been reported to French pharmacovigilance centers. This report of four cases of tendinopathy draws attention to a possible and heretofore unrecognized side effect of a drug class that is becoming increasingly popular. Statins are effective in lowering high cholesterol levels in patients with type IIa or IIb hypercholesterolemia. They have been widely used for the last decade, particularly in the secondary and primary prevention of major coronary events. Statins act by inhibiting the enzyme hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Although most patients tolerate statins extremely well, a few experience side effects requiring treatment discontinuation. Reported musculoskeletal side effects include myalgia and a few cases of rhabdomyolysis and polymyositis. Induced lupus and peripheral neuropathy are exceedingly rare. Joint Bone Spine 2001 68: 430-3. (C) 2001 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:430 / 433
页数:4
相关论文
共 10 条
[1]  
BEGAUD B, 1985, THERAPIE, V40, P111
[2]   In vitro study of cytotoxicity of quinolones on rabbit tenocytes [J].
Bernard-Beaubois, K ;
Hecquet, C ;
Hayem, G ;
Rat, P ;
Adolphe, M .
CELL BIOLOGY AND TOXICOLOGY, 1998, 14 (04) :283-292
[3]  
CHAZERAIN P, 2000, REV RHUM, V67, P320
[4]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[5]   Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study [J].
Nakahara, K ;
Kuriyama, M ;
Sonoda, Y ;
Yoshidome, H ;
Nakagawa, H ;
Fujiyama, J ;
Higuchi, I ;
Osame, M .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1998, 152 (01) :99-106
[6]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[7]  
RODOR F, 2000, THERAPIE, V55, P422
[8]  
Sack AL, 1996, J SPORT MANAGE, V10, P1
[9]   PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA [J].
SHEPHERD, J ;
COBBE, SM ;
FORD, I ;
ISLES, CG ;
LORIMER, AR ;
MACFARLANE, PW ;
MCKILLOP, JH ;
PACKARD, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1301-1307
[10]  
Tonkin A, 1998, NEW ENGL J MED, V339, P1349